These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11303788)

  • 1. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Child Neurology: Mucopolysaccharidosis IIID: Evidence From Ultrastructural and Genomic Study.
    Santhoshkumar R; Mahale RR; Kishore PK; Chickabasaviah YT
    Neurology; 2023 Oct; 101(15):e1572-e1576. PubMed ID: 37487748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC.
    Pan X; Caillon A; Fan S; Khan S; Tomatsu S; Pshezhetsky AV
    Cells; 2024 May; 13(10):. PubMed ID: 38786099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III.
    Mobini M; Radbakhsh S; Kubaski F; Eshraghi P; Vakili S; Vakili R; Abbasifard M; Jamialahmadi T; Rajabi O; Emami SA; Tayarani-Najaran Z; Rizzo M; Eid AH; Banach M; Sahebkar A
    Curr Med Chem; 2024; 31(20):3033-3042. PubMed ID: 37038706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders.
    De Risi M; Tufano M; Alvino FG; Ferraro MG; Torromino G; Gigante Y; Monfregola J; Marrocco E; Pulcrano S; Tunisi L; Lubrano C; Papy-Garcia D; Tuchman Y; Salleo A; Santoro F; Bellenchi GC; Cristino L; Ballabio A; Fraldi A; De Leonibus E
    Nat Commun; 2021 Jun; 12(1):3495. PubMed ID: 34108486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for mucopolysaccharidosis type III.
    Seker Yilmaz B; Davison J; Jones SA; Baruteau J
    J Inherit Metab Dis; 2021 Jan; 44(1):129-147. PubMed ID: 32944950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome.
    Canals I; Benetó N; Cozar M; Vilageliu L; Grinberg D
    Sci Rep; 2015 Sep; 5():13654. PubMed ID: 26347037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-Tau and Subunit c Mitochondrial ATP Synthase Accumulation in the Central Nervous System of a Woman with Hurler-Scheie Syndrome Treated with Enzyme Replacement Therapy for 12 Years.
    Kobayashi H; Ariga M; Sato Y; Fujiwara M; Fukasawa N; Fukuda T; Takahashi H; Ikegami M; Kosuga M; Okuyama T; Eto Y; Ida H
    JIMD Rep; 2018; 41():101-107. PubMed ID: 29705972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the human heparan-α-glucosaminide
    Navratna V; Kumar A; Rana JK; Mosalaganti S
    bioRxiv; 2024 Jun; ():. PubMed ID: 37961489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening and diagnosis of mucopolysaccharidoses.
    Tomatsu S; Fujii T; Fukushi M; Oguma T; Shimada T; Maeda M; Kida K; Shibata Y; Futatsumori H; Montaño AM; Mason RW; Yamaguchi S; Suzuki Y; Orii T
    Mol Genet Metab; 2013; 110(1-2):42-53. PubMed ID: 23860310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosaminoglycan storage disorders: a review.
    Coutinho MF; Lacerda L; Alves S
    Biochem Res Int; 2012; 2012():471325. PubMed ID: 22013531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi.
    Uversky VN; Kabanov AV; Lyubchenko YL
    J Proteome Res; 2006 Oct; 5(10):2505-22. PubMed ID: 17022621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery.
    Batrakova EV; Vinogradov SV; Robinson SM; Niehoff ML; Banks WA; Kabanov AV
    Bioconjug Chem; 2005; 16(4):793-802. PubMed ID: 16029020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New technologies for drug delivery across the blood brain barrier.
    Kabanov AV; Batrakova EV
    Curr Pharm Des; 2004; 10(12):1355-63. PubMed ID: 15134486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.
    Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ
    J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.
    Jones MZ; Alroy J; Downs-Kelly E; Lucas RE; Kraemer SA; Cavanagh KT; King B; Hopwood JJ
    J Mol Neurosci; 2004; 24(2):277-91. PubMed ID: 15456941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.